Summary：Hope Emerges as Researchers Reprogram Tumor Macrophages to Attack Cancer **Introduction** Scientis

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

Hope Emerges as Researchers Reprogram Tumor Macrophages to Attack Cancer

**Introduction**
Scientists have long known that tumor‑associated macrophages (TAMs) often slip into an M2‑like state, shielding cancer cells from immune attack and encouraging metastasis. A new strategy that flips these cellular bodyguards into tumor killers is generating excitement across oncology labs. By deploying tumor immune cell targeting chimeras (TICTs) designed to degrade the immune checkpoint receptor SIRPα, researchers are coaxing TAMs to adopt an M1‑like, cancer‑fighting phenotype. The approach could address a stubborn limitation of current immunotherapies: the immunosuppressive tumor microenvironment that blunts T‑cell activity.

**Key Developments**
A team at the University of California, San Francisco, recently published proof‑of‑concept data showing that a bifunctional molecule linking a macrophage‑specific nanobody to an SIRPα‑targeting degrader can reduce SIRPα levels by over 80 % in cultured TAMs. Loss of SIRPα disrupts the “don’t eat me” signal that cancer cells exploit, allowing macrophages to phagocytose tumor cells and secrete pro‑inflammatory cytokines such as IL‑12 and TNF‑α. In mouse models of breast cancer and melanoma, TICT treatment slowed tumor growth by up to 60 % and increased survival compared with checkpoint inhibitor monotherapy. Importantly, the chimeric construct showed minimal off‑target activity in peripheral blood monocytes, suggesting a favorable safety window.

**Industry Analysis**
The macrophage‑reprogramming niche is attracting both big pharma and venture capital. Companies such as Macrophage Therapeutics and Innate Pharma have initiated preclinical programs focused on SIRPα blockade, while several academic spin‑outs are exploring similar degrader‑based platforms. Analysts note that combining TICTs with existing PD‑1/PD‑L1 inhibitors could overcome resistance mechanisms that limit response rates to roughly 20‑